Hanson & Doremus Investment Management bought a new stake in Shire PLC (NASDAQ:SHPG) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 2,371 shares of the biopharmaceutical company’s stock, valued at approximately $436,000.
Other large investors have also made changes to their positions in the company. Renaissance Technologies LLC increased its stake in shares of Shire PLC by 12.6% in the first quarter. Renaissance Technologies LLC now owns 313,212 shares of the biopharmaceutical company’s stock worth $53,841,000 after buying an additional 35,100 shares during the last quarter. Reynolds Capital Management LLC purchased a new stake in shares of Shire PLC during the first quarter worth approximately $206,000. OLD Mission Capital LLC purchased a new stake in shares of Shire PLC during the first quarter worth approximately $28,179,000. Pictet Asset Management Ltd. increased its stake in shares of Shire PLC by 18.6% in the first quarter. Pictet Asset Management Ltd. now owns 147,339 shares of the biopharmaceutical company’s stock worth $23,001,000 after buying an additional 23,105 shares during the last quarter. Finally, Quadrature Capital Ltd purchased a new stake in shares of Shire PLC during the first quarter worth approximately $3,111,000. Institutional investors and hedge funds own 24.30% of the company’s stock.
Shire PLC (NASDAQ:SHPG) traded down 1.16% during trading on Monday, hitting $185.53. 615,835 shares of the company traded hands. The firm has a 50 day moving average of $194.68 and a 200 day moving average of $187.77. Shire PLC has a one year low of $147.60 and a one year high of $231.32. The firm has a market cap of $55.26 billion, a P/E ratio of 38.56 and a beta of 1.16.
Shire PLC (NASDAQ:SHPG) last released its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.03 by $0.35. The firm had revenue of $2.43 million for the quarter, compared to analyst estimates of $2.28 billion. Shire PLC had a net margin of 13.19% and a return on equity of 17.70%. The company’s revenue for the quarter was up 55.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.63 EPS. On average, analysts expect that Shire PLC will post $12.92 earnings per share for the current fiscal year.
The business also recently disclosed a dividend, which was paid on Friday, October 7th. Shareholders of record on Friday, September 9th were paid a $0.139 dividend. The ex-dividend date of this dividend was Wednesday, September 7th. Shire PLC’s dividend payout ratio is presently 15.63%.
A number of research analysts have issued reports on SHPG shares. Goldman Sachs Group Inc. reaffirmed a “buy” rating on shares of Shire PLC in a report on Tuesday, June 28th. HSBC cut shares of Shire PLC from a “buy” rating to a “hold” rating in a report on Monday, September 26th. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of Shire PLC in a report on Monday, October 3rd. Piper Jaffray Cos. set a $201.00 target price on shares of Shire PLC and gave the company a “hold” rating in a report on Saturday, October 1st. Finally, Shore Capital reaffirmed a “buy” rating on shares of Shire PLC in a report on Saturday, August 13th. Five analysts have rated the stock with a hold rating and twenty-two have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $228.15.
Shire PLC Company Profile
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.